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St. James’s Hospital, Dublin, Ireland
ABSTRACT
Malignant pleural mesothelioma (MPM) is a rare tumor that develops from the mesothelial linings of the pleural, pericardial, and 
peritoneal cavities. The actual risk factor for developing the disease is exposure to asbestos in workplace. Bromodomain and extraterminal 
(BET) domain proteins are epigenetic signaling agents that associate with acetylated histones and expedite the transcription of target 
genes. This study investigates whether the small molecule BET protein inhibitor JQ1 specifically may be an effective therapy for MPM. 
Reverse transcriptase polymerase chain reaction methods reveal an inclusive change in gene expression implying that JQ1 is a potential 
inhibitor which targets the BET proteins. Our results report that JQ1 has tumor-suppressive effects as it significantly ceased cellular 
activity in MPM cell lines. We predict that JQ1 may be the promising therapy for pleural mesothelioma cancers.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is an infrequent type of cancer that affects the pleura (the external lining of the lungs and the internal lining of the chest 
cavity). MPM includes three main types determined by their 
appearance under the microscope. MPM includes three main 
types determined by their appearance under the microscope as: 
Epithelial MPM which is the most popular form, Sarcomatoid 
MPM which is meant to be the most aggressive form and Biphasic 
MPM which mixes both Epithelial and Sarcomatoid MPMs. 
Pleural mesothelioma is commonly caused by the long-term 
exposure to asbestos fibers that induce pathogenic changes and 
eventually lead to cell injury, fibrosis, and possibly cancer. It has 
been also proposed that aside from asbestos, there are other 
factors which have a role in the tumor pathogenesis, such as SV40 
virus infection and genetic susceptibility.[1]
MPM incidence has been increasing over the world and 
is anticipated to grow even higher in the following 20 years 
due to asbestos huge spread exposure throughout the past 
10 years or so.[2] It is rated that about 50–80% of pleural 
malignant mesothelioma in men and 20–30% in women arose 
in individuals who were exposed to asbestos.[3]
Diagnosis of this disease is pretty much difficult even 
for some specialists because the symptoms do not appear 
only after a longer period of exposure to asbestos. So far, the 
only approved treatment for MPM is the combined therapy of 
pemetrexed and cisplatin, although currently, there have been 
many clinical trials determining the efficacy of other drugs.
Bromodomain and extraterminal (BET) domain proteins 
play an essential role as epigenetic reader molecules that are 
associated with acetylated histones and aid in the transcription 
of target genes. Bromodomain is, therefore, an acetyl-lysine-
binding motif of about 110 amino acids which are found in 
various transcription regulators and chromatin-modifying 
enzymes that are encoded by specific genes.[4] Research has 
shown that only members of the BET family (BRD2, BRD3, 
BRD4, and BRDT) may be prospective targets of cancer. These 
four BET proteins make up a subset of the larger family that 
consists of 46 proteins which contain 61 BRDs that have been 
determined in humans.[5]
BET inhibitors are getting to become of huge interest 
as a potential target due to the prospect that there might be 
biomarkers which will recognize the patients that may possibly 
benefit and respond to therapy. Those small molecule inhibitors 
conquer the acetyl-binding pockets of the bromodomains, 
leading in their detach from active chromatin and repression 
of downstream transcriptional targets.[6]
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JQ1 has started its journey in the research world as a novel 
drug in inhibiting the development of some specific cancers. 
JQ1 successfully blocks one of the well-known cancer-causing 
genes of the BET proteins which are BRD4, thereby preventing 
the early growth of some blood and lung cancers such as 
leukemia and multiple myeloma. JQ1 is a novel thieno-
triazolo-1,4-diazepine having an attached bulky t-butyl ester 
functional group at carbon 6. This chemical compound is a 
vigorous, high affinity, selective BET inhibitor. JQ1 detaches 
BET proteins from chromatin by binding to the acetyl-lysine 
recognition pocket of BET. JQ1 has been used as a chemical 
probe to investigate the role of BET in the transcriptional 
regulation of oncogenesis.[7-9]
BET inhibitors are a new promising treatment for MPM. 
This study will focus on the effect of the BET inhibitor (JQ1) in 
MPM. We hypothesized that bromodomains of the BET family 
are expressed/overexpressed in MPM and hence investigate 
the effect of the compound JQ1 as an inhibitor of those BET. 
This appears to be the first study of its kind, as far as I know 
that reveals the role of inhibiting BET domain proteins with 
JQ1 in mesothelioma cancers.
MATERIALS AND METHODS
Cell Lines
In this project, two MPM cell lines were treated with the 
small molecule BET protein inhibitor and were assessed for 
antiproliferative activity as a response to that drug. The BET 
inhibitor used in this study was JQ1. The two cell lines used 
were REN and H226. A brief description of the cell lines as 
follows:
•	 REN	is	an	epithelial	mesothelioma	cell	 line	(fast	growth	
rate)
•	 NCI-H226	 is	 an	 epithelial	 squamous	 cell	 carcinoma;	
mesothelioma cell line (slow growth rate).
Cell Culture
Cell lines were typically grown and preserved at a fixed 
temperature of 37°C and a humidified environment of 5% 
CO2 in a cell incubator. These cell lines were cultured in an 
appropriate cell culture media RPMI-1640 (Lonza, UK) which 
was supplemented with 10% (v/v) fetal bovine serum, 2 
mM L-glutamine, and 500 U/ml penicillin-streptomycin. Cell 
lines were regularly passaged in T75 cm2 flasks (Nunc Flasks 
obtained from Fisher Scientific, Ireland) as following:
All cell culture procedures were done in laminar flow 
hoods under sterile conditions. Cell media discarded and cells 
were washed with 5 ml phosphate buffer solution. Cells were 
then trypsinized for 5 min at 37°C, and once detached from the 
flask, media were added to make up a final volume of 10 ml. 
Cells were pipetted many times and each 1 ml transfer to two 
new T75 flasks labeled with the cell line, passage number, and 
date. Further, 9 ml of media was added to each of these two 
flasks and cells were incubated at 37°C. In this way, cells were 
split at a ratio of 1:10.
Cell Subculture for Proliferation assays
Before drug treatment, cells were visualized under the 
microscope (Nikon Corp.) and if found to be of about 70–80% 
confluent, they were trypsinized with 1.5 ml trypsin-EDTA and 
8.5 ml of media to make it up to a final volume of 10 ml. The 
cells were then counted using a bright-line hemocytometer 
(Sigma, USA) and seeded at 3×103 cells/well in 96-well plate. 
This was done in triplicate for both cell lines (REN and H226). 
The plated cells were kept in the incubator at 37°C.
Treatment of Cells
Once plated, cells were left to recover for 48 h. Subsequently, 
cells were treated with JQ1 BET domain inhibitor at the 
following concentrations (0.25 µM, 0.5 µM, 0.75 µM, 1 µM, 
15 µM, 20 µM, and 25 µM) for 48 h. 4 µl of dimethyl sulfoxide 
(DMSO) was added to the control as JQ1 was dissolved in DMSO 
vehicle. A concentrated stock (18.6 mM) of JQ1 dissolved in 
DMSO was made and further four stock dilutions (1:25, 1:10, 
1:5, and 1:2) were set up from that main concentrated stock. 
All plates were then incubated for 48 h at 37°C.
5-bromo-2-deoxyuridine (BrdU) 
Proliferation Assay
A BrdU assay was performed to measure the proliferative activity 
of the treated cells. Briefly, after cell treatment with JQ1 for 48 
h, all media were removed from the triplicate 96-well plate, 
and subsequently, 10 µl BrdU labeling solution was added to 
each well. Plates were incubated at 37°C for 4 h followed by 
the removal of the labeling medium from the wells. 200 µl 
FixDenat was added to each well and plates were incubated at 
25°C for 30 min followed by the removal of FixDenat solution 
thoroughly. 100 µl anti-BrdU POD solution was added to each 
well and plates were incubated again at 25°C for 90 min. The 
antibody was then removed and wells were rinsed 3 times 
with 200 µl/well washing solution. Finally, washing solution 
was removed and 100 µl/well substrate solution added to each 
well. Plates were left for 2–3 min and thence immediately 25 
µl/well of 1 M H2SO4 was added and measurement of plates 
was carried out within 5 min. The activity of proliferative cells 
was measured by enzyme-linked immunosorbent assay at a 
wavelength of 450 nm using a standard plate reader.
Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR)
Cell lines and tissue samples
Fresh-frozen mesothelial and benign pleural samples were 
collected following debulking surgery at Glenfield Hospital, 
Leicester, and were stored in The Leicestershire Mesothelioma 
Tissue Bank. Anonymized MPM specimens from 22 patients 
were transferred to St. James’ Hospital, Dublin. Approval for 
the storage and use of these samples have been obtained from 
the St. James’ Hospital/The Adelaide and Meath Hospital 
Research Ethics Committee. A panel of mesothelioma cell lines 
has been assembled and utilized for this project.
RNA isolation
Total RNA was isolated using TRI reagent® (MRC gene) 
protocol. Samples were mixed and incubated for 5 min at 
room temperature followed by centrifugation at 13,500 rpm 
for 5 min. The RNA pellet was left to air dry after the removal 
of the supernatant and finally resuspended in 30–50 µl of 
molecular	grade	water	and	stored	at	−80°C	until	further	use.
Albadri: Bromodomain inhibitor JQ1
72 http://journals.cihanuniversity.edu.iq/index.php/cuesj CUESJ 2020, 4 (1): 70-76
RNA quantification
NanoDrop 1000 spectrophotometer (Thermo Scientific) was 
used to measure the purity of the isolated RNA. 1 µl of each 
RNA sample was loaded separately onto the NanoDrop and 
analyzed. The quantity of RNA per sample was measured in 
ng/µl. A 260/280 value of 2.0 indicates the purity of an RNA 
sample.
Complementary DNA (cDNA) synthesis
cDNA was synthesized using RevertAid RT according to the 
manufacturer’s instructions (Fermentas). Samples were mixed 
gently, incubated for 90 min at 42°C followed by 10 min at 
70°C heating to terminate the reaction. The resultant cDNA 
was	then	stored	at	−20°C	until	required.
RT-PCR
The cDNA which was synthesized previously was used to 
detect gene expression. For PCR, the following were mixed 
in a new tube to set up the PCR reaction: 10 µl (2× GoTaq® 
Green [Promega]), 2 µl (5 µM of each forward and reverse 
primers), 6 µl (molecular grade water), and 1 µl (cDNA). 1 µl 
molecular grade water was added in the place of cDNA for the 
negative control. PCR samples were loaded on a thermocycler. 
The PCR cycling conditions involved initial denaturation at 
95°C for 5 min, followed by 30–35 cycles of denaturation at 
95°C, annealing at the temperature 58°C, extension at 72°C, 
and a final elongation step at 72°C.
Gel electrophoresis
Agarose gel (2%) was used for loading all PCR products. 
Agarose (2%) was dissolved in Tris-acetate-EDTA (TAE) 
in the microwave for 3 min. 4 µl of ethidium bromide was 
added per 25 ml of agarose solution after being cooled and 
then poured into a gel tray. The gel was then allowed to set at 
room temperature for 10–15 min. 4 µl of 100 bp DNA ladder 
(Fermentas) was loaded onto the gel in parallel with the samples. 
8 µl of each PCR product and 2 µl of the corresponding 18S 
housekeeping gene products were loaded as well. The samples 
were electrophoresed using an Electrophoresis Unit (Sigma) 
and 1× TAE was used as a running buffer. The gels were run 
at 80 volts for 30 min. The resultant bands were visualized 
and photographed under ultraviolet light using a biospectrum 
imaging system (Ultra Violet Products, Fusion FX, UK).
Statistical Analysis
Statistical analysis was carried out using two-tailed Student’s 
t-test and one-way ANOVA. Data were graphed as mean 
± standard error of mean using GraphPad Prism software. 
Densitometry analysis was performed using TINA software. 
Results were considered significant when the P < 0.05.
RESULTS
Screen of Panel of Mesothelioma Cell 
Lines for the Expression of BET Domain 
Proteins
A panel of 34 mesothelioma cell lines was screened for the 
expression of BRD2 and BRD4 (long and short transcript) 
variants. All these cell lines are MPMs, except for LP9, Met5A, 
NP1 and NP2, and P31 and P31CisR. Beta-actin was used as 
a positive control which is regularly expressed in all cell lines 
and a negative control was included also. BRD4 long transcript 
variant shows equal expression in all cell lines, but BRD4 short 
transcript shows a slightly lower expression in some of the cell 
lines [Figure 1]. BRD2 also shows an equal expression in all 
cell lines [Figure 2].
Screen of Primary MPM Patient Cells for 
the Expression of BET Domain Proteins
A panel of 34 primary mesothelioma cells obtained from 
patients was examined for the expression of BRD2 and BRD4 
(long and short transcript) variants. These patient samples 
were divided into benign and three histological subtypes of 
MPM;	 epithelial,	 biphasic,	 and	 sarcomatoid.	 Densitometry	
analysis was performed to identify the differences in 
expression of the BRDs between benign and tumor tissue 
following normalization against the 18S rRNA expression for 
each sample, and a negative control was used in each PCR. 
BRD2 showed expression across samples [Figure 3a] and was 
significantly less expressed in the tumor samples compared to 
benign [Figure 3b and c].
BRD4 long transcript variant appeared to be expressed 
across the three histological subtype samples and less expressed 
in benign [Figure 4a] and following statistical analysis, BRD4 
long transcript expression was significantly upregulated in 
Figure 1: Expression of BRD4 long and short transcript variants in a panel of 34 mesothelioma cell lines. Beta-actin is a positive control. BRD4 
long transcript is expressed uniformly in all cell lines and the expression of BRD4 short transcript is relatively less in some of the cell lines
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the tumor samples compared to benign [Figure 4b]. BRD4 
long transcript expression levels were significantly higher in 
epithelial and biphasic subtypes compared to benign, while 
not significant in sarcomatoid [Figure 4c]. On contrary, the 
expression of BRD4 short transcript variant appears to be 
almost entirely absent in the benign samples [Figure 5a] and 
BRD4 short transcript expression was significantly upregulated 
in the tumor samples compared to benign [Figure 5b]. While 
not significant, a trend toward upregulation of BRD4 short 
transcript was observed in all three histological subtypes of 
MPM compared to benign [Figure 5c].
Antiproliferative Activity
The BrdU assay detects incorporated BrdU into the cellular 
DNA of actively proliferating cells. This assay was performed 
to measure changes in proliferating cells after 48 h following 
treatment with JQ1 drug. REN-treated cells appear to show a 
significant decrease in proliferation activity with 5, 10, 15, 20, 
and 25 µM drug concentrations, while NCI-H226 treated cells 
appear to show significant decline in proliferation with 0.25, 
0.5, 0.75, 1, 15, and 25 µM drug concentrations [Figure 6]. 
The assay was accomplished in triplicate and the statistical 
analyses expressed as mean of treatments using one-way 
ANOVA and Dunnett’s multiple comparison test.
DISCUSSION
MPM is a rare and aggressive form of cancer with limited 
treatment chances that have inconsiderable impact on survival 
improvement. Asbestos has been known as a non-mutagenic 
carcinogen that induces mesothelioma and in such case, 
cancer may be developed as an outcome of somatic epigenome 
dysregulation.[10] And so, aberrant epigenetic events have been 
spotted in MPM. Epigenome regulators include DNA methylation, 
histone modifications, chromatin remodeling, and regulation 
of non-coding RNAs. It is not clear why precisely epigenetic 
modifications are a notable feature of pleural mesothelioma, 
Figure 2: Expression of BRD2 in a panel of 34 mesothelioma cell lines. Beta-actin is a positive control. BRD2 is uniformly expressed in all cell lines
Figure 3: BRD2 expression levels. (a) Reverse transcriptase polymerase chain reaction for BRD2 levels in a panel of primary patient malignant 
pleural mesothelioma samples of different histological subtypes against 18S rRNA housekeeping gene. (b) BRD2 expression level in malignant 
patients is significantly less compared to benign (***P < 0.001, two-tailed t-test). (c) Levels of BRD2 expression in all three histological subtypes 
is significantly different compared to benign (*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA using Dunnett’s multiple comparisons test). 
Error bars represent mean ± standard error of mean
a
b c
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but histone modifications have emerged as remarkable 
modifications in the carcinogenesis of MPM.[11] Aberrant 
regulation of histone modification plays a role in oncogenesis by 
affecting gene activity. The acetylation of histones is mediated 
by lysine acetyltransferases. Lysine acetylation is mainly 
recognized by bromodomains and tandem PHD domains.[12] 
BET proteins are readers of acetyl-lysine signs. In some cancer 
types, bromodomain-containing proteins which identify histone 
acetylation signs are mistargeted or overexpressed.[13]
This study focuses precisely on the role of two BET 
proteins, BRD2 and BRD4, in MPM and the effect of JQ1 
compound as an inhibitor for BRDs. The expression of these 
BET proteins in MPM has been evaluated in a panel of 
mesothelioma cell lines and in primary MPM patient cells. 
A panel of cell lines [Figures 1 and 2] was screened to evaluate 
whether there are any prominent patterns of expression which 
need to be identified before screening of primary MPM patient 
cells. Slight changes in expression were noted. BRD4 short 
transcript variant is expressed weakly in some of the cell lines. 
Among the analyzed cell lines are a cisplatin resistance cell 
line. Cisplatin is a chemotherapeutic agent used in cancer 
treatment. A specific feature of MPM is that it is a cisplatin 
resistance tumor.[14] Although there were no remarkable 
variations in the expression level of any of the evaluated BRDs, 
additional MPM chemoresistant cell lines need to be included 
so that it would be a conclusive analysis.
Figure 4: BRD4 long transcript expression levels. (a) Reverse transcriptase polymerase chain reaction for BRD4L levels in a panel of primary 
patient malignant pleural mesothelioma samples of different histological subtypes against 18S rRNA housekeeping gene. (b) BRD4L expression 
level in tumor patients is significantly different compared to benign (***P < 0.001, two-tailed t-test). (c) Levels of BRD4L expression epithelial 
and biphasic subtypes are significantly different compared to benign, while not significantly different in sarcomatoid subtype (**P < 0.01, 
***P < 0.001, one-way ANOVA using Dunnett’s multiple comparisons test). Error bars represent mean ± standard error of mean
a
b c
Figure 5: BRD4 short transcript expression levels. (a) Reverse transcriptase polymerase chain reaction for BRD4S levels in a panel of primary 
patient malignant pleural mesothelioma samples of different histological subtypes against 18S rRNA housekeeping gene. (b) BRD4S expression 
level in tumor patients is significantly different compared to benign (*P < 0.05, two-tailed t-test). (c) Levels of BRD4S expression in all three 
histological subtypes show no significance compared to benign (one-way ANOVA using Dunnett’s multiple comparisons test). Error bars represent 
mean ± standard error of mean
a
b c
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Subsequently, a panel of primary MPM patient cells 
including benign, epithelioid, sarcomatoid, and biphasic 
histological subtypes was screened [Figures 3-5]. Expression 
of the three evaluated BRDs varies in malignant compared to 
benign cells. Expression of BRD2 was significantly different 
in malignant cells compared to benign cells. In addition, all 
three histological subtypes showed significantly lower levels 
of BRD2 expression compared to benign even though BRD2 
was expressed in benign. On contrary, BRD4 long transcript 
expression levels are significantly higher in malignant cells 
compared to benign. In consistent with the results of BRD4 
long transcript expression levels, the expression of BRD4 short 
transcript confirmed significantly elevated levels in malignant 
cells compared to benign, and this indicates that BRD4 long 
and short transcripts are overexpressed in malignant cell. Our 
findings have proven that BRD2 is downregulated in MPM 
tumors, while BRD4 long and short transcripts are significantly 
upregulated in MPM tumors. Moreover, since BRD4 is the main 
target for JQ1, consequently, this makes targeting MPM with 
JQ1 and excellent strategy.
To further support our findings, the antiproliferative 
activity of JQ1 was evaluated in vitro using two specific 
MPM cell lines (REN and NCI-H226). These two cell lines 
were chosen according to their common use in human tumor 
xenografts, as they perform well when xenograft in mouse 
models and so, the evaluation of JQ1 drug can be smoothly 
carried out in such in vivo models. JQ1 is a BET inhibitor 
that has been selected for this study. Scientists have been 
competing to develop novel BET protein inhibitors. A recently 
developed dihydroquinazoline-2-one inhibitor has been found 
to target BET.[15] BrdU assay was the first move in analyzing 
the proliferative activity of JQ1 compound. This assay detects 
BrdU incorporated into the newly synthesized DNA of actively 
proliferating cells. BrdU assay was chosen to measure the 
proliferating activity of cells. REN and NCI-H226 cells were 
treated with a range of JQ1 concentrations [Figure 6]. 
Response of NCI-H226 cells to JQ1 was clearly observed, with a 
significant decrease in cell proliferation starting from 0.25 µM 
up to 25 µm concentrations compared to untreated cells. While 
REN cells showed a significant decrease in proliferative activity 
with concentrations from 5 µM up to 25 µM. DMSO was used 
as a control to ensure that any change in proliferative activity 
was caused by JQ1 and not DMSO. DMSO induced no change 
in the cellular activity of both cell lines and so, noted results 
are accurate. JQ1 inhibits the proliferative activity of REN and 
NCI-H226 cells with concentrations of 5 µM and 0.25 µM, 
respectively. JQ1 has shown to have antiproliferative effects 
on mesothelioma cell lines and efficiently abrogates their 
clonogenic growth. Exposure of sensitive cell lines with JQ1 
results in decreased proliferative cell activity and induction 
of apoptosis. In addition to confirming the effect of JQ1, the 
BrdU also provided a guideline for treatment concentrations to 
be used in a further study.
CONCLUSION
This study has shown that BET domain proteins BRD2 and 
BRD4 are significantly altered in the tumors of patients 
suffering from MPM. Critically levels of BRD4 are significantly 
elevated in the tumors. JQ1 is a small molecule inhibitor of 
BRD4 and BRD2. This study has shown that JQ1 may be a 
potentially effective therapy for MPM in vitro.
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